Does Benadryl cause dementia? Everyday medications and your brain

If you reach for Benadryl now and then for hay fever or a rough night, this is not a reason to panic. But the honest answer is worth knowing: Benadryl's active ingredient, diphenhydramine, is a strong anticholinergic — a type of drug that blocks acetylcholine, a chemical your brain uses for memory and learning. Large studies have linked heavy, long-term use of anticholinergic medicines to a higher risk of dementia — in one cohort, about 54% higher at the highest cumulative doses. The caveat you'll rarely see in a headline: this is an association, not proven cause, and it concerns sustained use over years, not the occasional tablet. Here's what the evidence actually supports — and what to do about it, safely.

Does Benadryl cause dementia?

Benadryl (diphenhydramine) is a strong anticholinergic, and large studies link heavy, long-term anticholinergic use to higher dementia risk — roughly 50% higher at the highest doses. But this is an association, not proven cause, and it concerns years of regular use, not an occasional tablet.

What makes Benadryl an "anticholinergic"?

Most people think of Benadryl as a simple allergy pill, but its active ingredient — diphenhydramine — does more than calm a runny nose. It's a first-generation antihistamine, and this older class also blocks acetylcholine, one of the brain's key messengers for memory, attention and learning. Drugs that do this are called anticholinergic, and diphenhydramine is one of the stronger ones you can buy without a prescription.

That anticholinergic effect is also why Benadryl makes you drowsy and foggy — and why it turns up in so many night-time and "PM" products. ZzzQuil, Tylenol PM, Advil PM and many store-brand sleep aids are often diphenhydramine under another name. Newer allergy medicines such as loratadine (Claritin), cetirizine (Zyrtec) and fexofenadine (Allegra) were designed to stay out of the brain and carry little or no anticholinergic burden.

The distinction that matters most is occasional versus regular. A single dose for a bee sting or one bad night is a very different thing from taking an anticholinergic most nights for years — and it's the second pattern the research is concerned with.

What the anticholinergic studies actually found

Two large, careful studies anchor the concern, and both point the same direction:

• A 2015 cohort in JAMA Internal Medicine (Gray and colleagues) followed about 3,400 adults aged 65 and older, using pharmacy records rather than memory to measure exposure. People with the highest cumulative anticholinergic use had roughly a 54% higher risk of dementia (hazard ratio 1.54) than non-users, and the risk rose with the total dose taken over a decade.
• A 2019 nested case-control study in the same journal (Coupland and colleagues) analysed English records for nearly 285,000 people. Heavy use of certain anticholinergics — including some antidepressants, bladder drugs, antipsychotics and anti-Parkinson's medicines — was linked to about a 49% higher risk (odds ratio 1.49).

Those numbers sound alarming, so hold on to two things. First, this is association, not proof of cause: people who take a lot of these drugs may differ in ways that are hard to fully account for, and some anticholinergics treat early symptoms — like low mood or disturbed sleep — that can themselves precede dementia. Second, the signal is strongest for years of high-dose use. An ordinary hay-fever season is not the scenario these studies describe.

It's also worth knowing diphenhydramine is far from the only strong anticholinergic. Older tricyclic antidepressants (such as amitriptyline), bladder drugs (such as oxybutynin) and some antipsychotics carry a similar burden — which is why the sensible response is a full medication review, not simply swapping one pill.

How much counts as "heavy use"?

This is the question the headlines never answer, and the 2015 study does. It measured exposure in total standardised daily doses (TSDDs) — essentially, how many days' worth of a normal dose someone had taken over ten years. The risk did not appear all at once; it climbed with the total:

• 1 to 90 TSDDs — hazard ratio 0.92, meaning no increased risk was detected at all.
• 91 to 365 — hazard ratio 1.19.
• 366 to 1,095 — hazard ratio 1.23.
• More than 1,095 — hazard ratio 1.54, the figure that gets quoted.

To land in that highest group you would have to take the minimum effective daily dose of a strong anticholinergic every day for more than three years. That is the pattern the 54% figure describes. It is not a description of taking Benadryl for a week of hay fever, and the lowest exposure band showed no raised risk at all.

The practical read: these studies track a running total. If you have used a lot in the past, the useful question is not what has already happened but whether the total is still going up.

If I stop taking it, does the risk go away?

Two different things get tangled together here, and separating them helps.

The short-term fog does lift. Anticholinergics cause confusion, drowsiness and poor recall while they are in your system, particularly in older adults. That effect is well recognised, it is a large part of why these drugs appear on lists of medicines to use cautiously in later life, and it settles once the drug clears. If Benadryl leaves you woolly the next morning, that part is not permanent damage.

The longer-term question is genuinely unanswered. Both studies above are observational: they watched what happened to people who had already taken these drugs. That design can show a link with cumulative exposure, but it cannot tell you whether stopping undoes anything, and no trial has been run to find out. Anyone telling you confidently that quitting reverses the risk is going beyond the evidence, in the same way as anyone telling you a few tablets caused a diagnosis.

What follows is modest and worth doing anyway: not adding to the total is within your control, and a second-generation antihistamine or a different approach to sleep usually does the job. Do not stop a prescribed medicine on your own. Several drugs on the anticholinergic list are treating something that matters more than this risk does, and that trade-off belongs to the person who prescribed it.

Sleeping pills and Xanax: what the evidence says

If Benadryl worries you, sleeping pills are the natural next question — and here the story is more reassuring, with a catch.

Many over-the-counter sleep aids are simply diphenhydramine, so the anticholinergic caution above applies to them directly. Prescription benzodiazepines — such as alprazolam (Xanax), diazepam (Valium) and lorazepam (Ativan) — are a different drug class. Early studies raised alarm, but a 2016 BMJ study that tracked benzodiazepine use carefully found no higher risk at the highest exposure levels and concluded the data "do not support a causal association between benzodiazepine use and dementia." A likely explanation for the earlier scares: anxiety, insomnia and broken sleep are themselves early signs of dementia, so the pills may be a marker rather than a cause.

That's genuinely reassuring on the dementia question specifically — but benzodiazepines carry other real risks in older adults, including sedation, confusion and falls, and they can be habit-forming. So "probably not a dementia cause" is not the same as "harmless," and how long you stay on one is a conversation for your doctor. If poor sleep is the real problem, it's worth reading how sleep itself affects dementia risk.

Omeprazole, statins and the rest of the cabinet

Two more everyday medicines get named a lot, and the news on both is largely calm.

Proton pump inhibitors (PPIs) — omeprazole, esomeprazole, lansoprazole and the like, taken for reflux — have produced mixed results. Some studies hinted at a link with very long cumulative use (a 2023 analysis found a modest rise only after more than four years), but a large 2023 study drawn from a randomized trial (ASPREE) found no association between PPI use and dementia or cognitive decline. On balance, the better-designed evidence does not support a robust causal link.

Statins, the cholesterol drugs, are the reassuring outlier: they are consistently associated with lower dementia risk, not higher. A meta-analysis pooling more than nine million people found roughly 17% lower all-cause dementia risk among statin users. That's observational too, so it can't prove the drug is protective — but it's a firm counter to the fear that statins harm the brain. There's more in our piece on cholesterol, statins and dementia.

What to do — safely

The single most important rule: never stop, start or change a prescribed medicine on your own because of an article like this. Stopping suddenly can be more dangerous than the theoretical risk you're worried about — and the decision to reduce or swap a drug (deprescribing) is a clinical judgement that weighs your whole health, not one headline.

What you can safely do:

• Book a medication review. Bring every pill you take — prescription and over-the-counter — to your doctor or pharmacist and ask whether any are strongly anticholinergic, and whether they're all still needed.
• Check your own cabinet for hidden diphenhydramine. Read the active ingredient on allergy and "PM" sleep products; if it's diphenhydramine and you use it most nights, that's worth raising.
• Ask about gentler swaps. A newer non-drowsy antihistamine, or a non-drug approach to sleep, may do the same job with far less anticholinergic load — but let your clinician make that call.
• Keep the risk in proportion. Occasional use is not what the studies flag. Consistent, long-term use is the pattern worth reviewing — calmly, and with a professional.

Medications are only one lever among many. If you want the fuller picture of what you can influence, see can you reduce your dementia risk?

How we research and review our content →

This article is educational and is not medical advice, diagnosis, or treatment. The studies cited — including the 2015 and 2019 JAMA Internal Medicine anticholinergic studies, the 2016 BMJ benzodiazepine study, the 2023 ASPREE and ARIC proton-pump-inhibitor analyses, and the observational statin meta-analysis — describe associations across populations, not proven cause and effect, and none refer to Solenna. Solenna does not diagnose, prevent, treat, or cure Alzheimer's disease or any form of dementia, and individual results vary. Never start, stop, or change any medication — including Benadryl, sleeping pills, benzodiazepines, proton pump inhibitors or statins — based on this article; medication decisions and deprescribing belong with your doctor or pharmacist, who knows your full health.